These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28640529)

  • 21. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
    Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
    Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early Conversion to Everolimus Within 180 Days of Living Donor Liver Transplantation.
    Rudzik KN; Schonder KS; Humar A; Johnson HJ
    Clin Transplant; 2024 Jul; 38(7):e15402. PubMed ID: 39023099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Wound complications and surgical events in de novo heart transplant patients treated with everolimus: Post-hoc analysis of the SCHEDULE trial.
    Rashidi M; Esmaily S; Fiane AE; Gude E; A Tønseth K; Ueland T; Gustafsson F; Eiskjær H; Rådegran G; Dellgren G
    Int J Cardiol; 2016 May; 210():80-4. PubMed ID: 26938682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating delta-like Notch ligand 1 is correlated with cardiac allograft vasculopathy and suppressed in heart transplant recipients on everolimus-based immunosuppression.
    Norum HM; Michelsen AE; Lekva T; Arora S; Otterdal K; Olsen MB; Kong XY; Gude E; Andreassen AK; Solbu D; Karason K; Dellgren G; Gullestad L; Aukrust P; Ueland T
    Am J Transplant; 2019 Apr; 19(4):1050-1060. PubMed ID: 30312541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Everolimus-based Immunosuppression Possibly Suppresses Mean Fluorescence Intensity Values of De Novo Donor-specific Antibodies After Primary Kidney Transplantation.
    Narumi S; Watarai Y; Goto N; Hiramitsu T; Tsujita M; Okada M; Futamura K; Tomosugi T; Nishihira M; Sakamoto S; Kobayashi T
    Transplant Proc; 2019 Jun; 51(5):1378-1381. PubMed ID: 31056252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
    Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal Function Changes Under Everolimus Plus Cyclosporine or Everolimus Plus Tacrolimus After Heart Transplantation.
    Chiang TY; Tsao CI; Wang SS
    Transplant Proc; 2018 Nov; 50(9):2756-2758. PubMed ID: 30401391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
    Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association Between Renal Dysfunction and Major Adverse Cardiac Events After Liver Transplantation: Evidence from an International Randomized Trial of Everolimus-Based Immunosuppression.
    Saliba F; Fischer L; de Simone P; Bernhardt P; Bader G; Fung J
    Ann Transplant; 2018 Oct; 23():751-757. PubMed ID: 30361470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term cardiovascular outcome of renal transplant recipients after early conversion to everolimus compared to calcineurin inhibition: results from the randomized controlled MECANO trial.
    van Dijk M; van Roon AM; Said MY; Bemelman FJ; Homan van der Heide JJ; de Fijter HW; de Vries APJ; Bakker SJL; Sanders JSF
    Transpl Int; 2018 Dec; 31(12):1380-1390. PubMed ID: 30106185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do patient characteristics influence efficacy and renal outcomes in liver transplant patients receiving everolimus?
    De Simone P; Saliba F; Dong G; Escrig C; Fischer L
    Clin Transplant; 2016 Mar; 30(3):279-88. PubMed ID: 26717035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The MANDELA study: A multicenter, randomized, open-label, parallel group trial to refine the use of everolimus after heart transplantation.
    Deuse T; Bara C; Barten MJ; Hirt SW; Doesch AO; Knosalla C; Grinninger C; Stypmann J; Garbade J; Wimmer P; May C; Porstner M; Schulz U
    Contemp Clin Trials; 2015 Nov; 45(Pt B):356-363. PubMed ID: 26363128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Everolimus Initiation and Corticosteroid Weaning During Acute Phase After Heart Transplantation on Clinical Outcome: Data from the Korean Organ Transplant Registry (KOTRY).
    Lee KS; Kim H; Lee SH; Choi DJ; Yoon M; Jeon ES; Choi JO; Kang J; Lee HY; Jung SH; Oh J; Kang SM; Lee SY; Ju MH; Kim JJ; Kim MS; Cho HJ
    Transpl Int; 2024; 37():11878. PubMed ID: 38644935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive function after heart transplantation: Comparing everolimus-based and calcineurin inhibitor-based regimens.
    Bürker BS; Gullestad L; Gude E; Relbo Authen A; Grov I; Hol PK; Andreassen AK; Arora S; Dew MA; Fiane AE; Haraldsen IR; Malt UF; Andersson S
    Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28185318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 3-month, Multicenter, Randomized, Open-label Study to Evaluate the Impact on Wound Healing of the Early (vs Delayed) Introduction of Everolimus in De Novo Kidney Transplant Recipients, With a Follow-up Evaluation at 12 Months After Transplant (NEVERWOUND Study).
    Manzia TM; Carmellini M; Todeschini P; Secchi A; Sandrini S; Minetti E; Furian L; Spagnoletti G; Pisani F; Piredda GB; Cappelli G; Tisone G
    Transplantation; 2020 Feb; 104(2):374-386. PubMed ID: 31335776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppressive Effect of Everolimus on IL-2, IL-10, IL-21, and IFNγ Levels: Implications for the Successful Minimization of Calcineurin Inhibitor Use in Transplantation.
    Iwasaki K; Kitahata N; Miwa Y; Uchida K; Matsuoka Y; Horimi K; Kobayashi T
    Ther Drug Monit; 2019 Jun; 41(3):371-375. PubMed ID: 30939587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation.
    Chapman WC; Brown RS; Chavin KD; Sudan D; Koneru B; Junge G; Dong G; Patel D; Teperman L; Fung JJ
    Transplantation; 2017 Feb; 101(2):341-349. PubMed ID: 28121741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of conversion from calcineurin inhibitors to everolimus on hepatitis C viremia in adult kidney transplant recipients.
    Pacheco LS; Garcia VD; Prá RLD; Cardoso BD; Rodrigues MF; Zanetti HK; Meinerz G; Neumann J; Gnatta D; Keitel E
    J Bras Nefrol; 2018; 40(2):143-150. PubMed ID: 29771270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Everolimus and reduced calcineurin inhibitor therapy in pediatric liver transplant recipients: Results from a multicenter, prospective study.
    Ganschow R; Ericzon BG; Dhawan A; Sharif K; Martzloff ED; Rauer B; Ng J; Lopez P
    Pediatr Transplant; 2017 Nov; 21(7):. PubMed ID: 28714558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of everolimus with reduced-exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial.
    Carmellini M; Garcia V; Wang Z; Vergara M; Russ G
    J Nephrol; 2015 Oct; 28(5):633-9. PubMed ID: 25708913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.